Get the Stockscreener App
22.50
0.66%
-0.15
After Hours:
22.30
-0.20
-0.89%
Definium Therapeutics Inc stock is traded at $22.50, with a volume of 1.23M.
It is down -0.66% in the last 24 hours and down -2.51% over the past month.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
See More
Previous Close:
$22.65
Open:
$22.85
24h Volume:
1.23M
Relative Volume:
0.72
Market Cap:
$2.45B
Revenue:
-
Net Income/Loss:
$-183.79M
P/E Ratio:
-10.87
EPS:
-2.0691
Net Cash Flow:
$-131.84M
1W Performance:
+7.19%
1M Performance:
-2.51%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$22.34
$23.10
1-Week Range:
$19.33
$23.10
52-Week Range:
$14.62
$26.25
Definium Therapeutics Inc Stock (DFTX) Company Profile
Name
Definium Therapeutics Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
22.50 | 2.47B | 0 | -183.79M | -131.84M | -2.0691 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | Stifel | Buy |
| Apr-10-26 | Initiated | Piper Sandler | Overweight |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-30-26 | Initiated | Jefferies | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Aug-04-25 | Resumed | Oppenheimer | Outperform |
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Definium Therapeutics Inc Stock (DFTX) Latest News
Definium Therapeutics eyes key DT-120 depression data, advances anxiety program - MSN
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program - TradingView
Definium Therapeutics (DFTX) Short Interest & Short Float | Updated May 2026 - MarketBeat
Jefferies Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $35 - Moomoo
Definium Therapeutics: High-Stakes Data Readouts Poised To Validate Best-In-Class Potential - Seeking Alpha
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Business Wire
Definium Begins Second Phase 3 DT120 Trial As Valuation Gap Widens - Yahoo Finance
Definium Therapeutics Nears Pivotal Earnings Call Tests - The Globe and Mail
Definium Therapeutics convenes lawmakers and researchers to advance psychedelic medicine discourse - Traders Union
DFTX Stock Price, Quote & Chart | DEFINIUM THERAPEUTICS INC (NASDAQ:DFTX) - ChartMill
Definium Therapeutics Advances DT120 ODT for GAD and MDD With Promising Phase 3 Data and Billion-Dollar Market Potential - Minichart
Definium Highlights Late-Stage Psychedelic-Inspired Psychiatric Pipeline - TipRanks
Definium Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Definium posts May 2026 corporate presentation outlining Phase 3 DT120 readouts and $373.4M cash - TradingView
Definium Therapeutics (NASDAQ: DFTX) maps DT120 Phase 3 path and 2026 data - Stock Titan
Definium Therapeutics presents pre-clinical safety data on new psychedelic treatment at APA meeting - Traders Union
Definium Therapeutics (DFTX) Institutional Ownership 2026 - MarketBeat
Trump's psychedelic drug order boosts investor interest with promise of faster reviews - Reuters
Definium Therapeutics, Inc.Common Shares (NQ: DFTX - The Chronicle-Journal
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Deep Track entities disclose 3.01% stake in Definium Therapeutics (DFTX) - Stock Titan
Definium Therapeutics (DFTX) stock gains after hours: Here's what's driving the move - MSN
H.C. Wainwright Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $70 - Moomoo
Definium Therapeutics (DFTX) Is Down 6.0% After Starting Second Phase 3 DT120 Trial in MDDHas The Bull Case Changed? - Sahm
Definium Therapeutics launches pivotal Phase 3 Ascend trial in major depressive disorder - Traders Union
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics Doses First Patient in Phase 3 Ascend Trial of DT120 ODT (LSD) for Major Depressive Disorder - Minichart
Definium Therapeutics (DFTX) Begins Phase 3 Study for Major Depr - GuruFocus
Definium doses first patient in second phase 3 depression study - Investing.com UK
Definium Therapeutics Begins Patient Dosing in Ascend Phase 3 Depression Trial - marketscreener.com
Definium begins second Phase 3 trial for DT120 - TipRanks
Definium Therapeutics says first patient dosed in Ascend study - TipRanks
Definium Therapeutics doses first patient in Phase 3 Ascend trial of DT120 ODT for MDD - TradingView
Definium Therapeutics (DFTX) doses first patient in Ascend Phase 3 DT120 depression trial - Stock Titan
DFTX.O - Reuters
Definium Therapeutics announces first patient dosed in Ascend - marketscreener.com
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder - The Joplin Globe
Definium Therapeutics engages at Fierce Biotech Week with industry communications leaders - Traders Union
Definium Therapeutics Announces New Employee Inducement Grants - Yahoo Finance
Biotech Definium offers stock options to five new hires - Stock Titan
A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $25 to $61 - Moomoo
Definium Therapeutics, Inc. (DFTX) Price To Cash Flow - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: Alcon (ALC), Argenx Se (ARGX) and Definium Therapeutics (DFTX) - The Globe and Mail
Definium Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Definium Therapeutics (DFTX) Deepens Losses Advancing Psychedelic Pipeline Is Its Cash Strategy Still Coherent? - Yahoo Finance
RBC Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $36 - Moomoo
DFTX Maintained by Piper Sandler -- Price Target Lowered to $48 - GuruFocus
A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $36 to $48 - Moomoo
DFTX SEC FilingsDefinium Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
DFTX: Definium Therapeutics Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Definium Therapeutics Inc Stock (DFTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):